Repeated treatment with the synthetic cannabinoid WIN 55,212-2 reduces both hyperalgesia and production of pronociceptive mediators in a rat model of neuropathic pain

B. Costa, M. Colleoni, S. Conti, A. E. Trovato, M. Bianchi, M. L. Sotgiu, G. Giagnoni

Research output: Contribution to journalArticlepeer-review

Abstract

The antinociceptive properties of cannabinoids in persistent pain are not fully elucidated. We investigated the effect of repeated treatment with the synthetic cannabinoid receptor agonist WIN 55,212-2 on the neuropathic pain induced in rats by chronic constriction of the sciatic nerve. WIN 55,212-2 administered daily throughout the development of neuropathy reversed the hyperalgesia, at a dose (0.1 mg kg -1, s.c.) that had no effect on the nociceptive responses of either paw contralateral to the sciatic ligation or of animals subjected to sham surgery. At 14 days after injury, the levels of mediators known to be involved in neuropathic pain, such as prostaglandin E2, NO and the neuronal NOS, were increased. Repeated treatment with WIN 55,212-2 abolished these increases. In the light of the current clinical need for neuropathic pain treatments, these findings indicate that cannabinoid agonists, at doses devoid of psychoactive effects, could constitute important compounds for the development of new analgesics.

Original languageEnglish
Pages (from-to)4-8
Number of pages5
JournalBritish Journal of Pharmacology
Volume141
Issue number1
DOIs
Publication statusPublished - Jan 2004

Keywords

  • Endogenous cannabinoid system
  • Neuropathic pain
  • Nitric oxide system
  • WIN 55,212-2

ASJC Scopus subject areas

  • Pharmacology

Fingerprint Dive into the research topics of 'Repeated treatment with the synthetic cannabinoid WIN 55,212-2 reduces both hyperalgesia and production of pronociceptive mediators in a rat model of neuropathic pain'. Together they form a unique fingerprint.

Cite this